. 2019 Dec 16;29(12):1792–1803. doi: 10.1089/thy.2019.0328

Table 3.

Nodal Status and BRAF/NRAS Mutation According to the Percentage of Papillae Within the Tumor in Unifocal Encapsulated Papillary Thyroid Carcinoma

	Percentage of papillae
	0%	0.1–0.9%	1–9%	10–24%	25–49%	≥50%
All cases
pN stage
N0/NX	127 (100%)	31 (100%)	13 (93%)	4 (67%)	5 (100%)	28 (54%)
N1	0 (0%)	0 (0%)	1 (7%)^a	2 (33%)	0 (0%)	24 (46%)
RAS/BRAF
BRAF^V600E	1 (2.5%)^b	1 (4%)^c	0 (0%)	1 (25%)	3 (75%)	18 (82%)
NRAS^Q61R	15 (37.5%)	10 (42%)	1 (17%)	0 (0%)	0 (0%)	0 (0%)
Negative	24 (60%)	13 (54%)	5 (83%)	3 (75%)	1 (25%)	4 (18%)
Invasive cases
pN stage
N0/NX	27 (100%)	11 (100%)	4 (80%)	2 (67%)	3 (100%)	17 (57%)
N1	0 (0%)	0 (0%)	1 (20%)^a	1 (33%)	0 (0%)	13 (43%)
RAS/BRAF
BRAF^V600E	0 (0%)	0 (0%)	0 (0%)	1 (100%)	2 (100%)	10 (91%)
NRAS^Q61R	1 (25%)	5 (56%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Negative	3 (75%)	4 (44%)	1 (100%)	0 (0%)	0 (0%)	1 (9%)
Noninvasive cases
pN stage
N0/NX	100 (100%)	20 (100%)	9 (100%)	2 (67%)	2 (100%)	11 (50%)
N1	0 (0%)	0 (0%)	0 (0%)	1 (33%)^d	0 (0%)	11 (50%)
RAS/BRAF
BRAF^V600E	1 (3%)^b	1 (7%)^c	0 (0%)	0 (0%)	1 (50%)	8 (73%)
NRAS^Q61R	14 (39%)	5 (33%)	1 (20%)	0 (0%)	0 (0%)	0 (0%)
Negative	21 (58%)	9 (60%)	4 (80%)	3 (100%)	1 (50%)	3 (27%)

The difference in BRAF^V600E positivity and NRAS^Q61R positivity between cases with ≥10% papillae and those with <10% papillae is highly significant (Fisher's exact test, p < 0.001).

^{^a}

The percentage of papillae within this encapsulated tumor with capsular invasion was 5%; both the primary tumor and the nodal metastasis were negative for BRAF^V600E and NRAS^Q61R.

^{^b}

A 0.2-cm noninvasive well-circumscribed tumor composed entirely of follicles. No true papillae were identified on multiple histologic levels examined.

^{^c}

A 1.5-cm noninvasive encapsulated lesion with 10% of total tumor volume showing tall cell cytomorphology.

^{^d}

The percentage of papillae within this noninvasive encapsulated tumor with lymph node metastasis was 10%.